Opportunity ID: 353198

General Information

Document Type: Grants Notice
Funding Opportunity Number: HT942524OCRPCTTERA
Funding Opportunity Title: DoD Ovarian Cancer Clinical Trial Translational Endpoints Research Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 1
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Mar 26, 2024
Last Updated Date: Aug 01, 2024
Original Closing Date for Applications: Aug 06, 2024
Current Closing Date for Applications: Aug 06, 2024
Archive Date: Sep 05, 2024
Estimated Total Program Funding: $1,600,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description:

The FY24 OCRP Clinical Trial Translational Endpoints Research Award intends to support correlation of clinical trial-related data (e.g., biosample analysis, imaging, or epidemiological data) with clinical outcomes or responses to therapies. Correlative studies may be associated with a past, ongoing, or future clinical trial in order to associate various factors (genetic, DOD FY24 Ovarian Cancer Clinical Trial Translational Endpoints Research Award 4

biochemical, environmental and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. The proposed research may be hypothesis testing or may be designed to generate new hypotheses to be tested in follow-up clinical research. The award may not be used to directly support a clinical trial.

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

Version History

Version Modification Description Updated Date
We are adding a 6-day grace period for those impacted by Hurricane Beryl.

Please also note, that if you submit an application during the grace period, then you must also submit an appeal to the eBRAP help desk to explain how you were affected by the storm. If you do not submit an appeal with your grace period application, then your application will not be accepted.

Aug 01, 2024
Mar 26, 2024

DISPLAYING: Synopsis 2

General Information

Document Type: Grants Notice
Funding Opportunity Number: HT942524OCRPCTTERA
Funding Opportunity Title: DoD Ovarian Cancer Clinical Trial Translational Endpoints Research Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 1
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Mar 26, 2024
Last Updated Date: Aug 01, 2024
Original Closing Date for Applications: Aug 06, 2024
Current Closing Date for Applications: Aug 06, 2024
Archive Date: Sep 05, 2024
Estimated Total Program Funding: $1,600,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description:

The FY24 OCRP Clinical Trial Translational Endpoints Research Award intends to support correlation of clinical trial-related data (e.g., biosample analysis, imaging, or epidemiological data) with clinical outcomes or responses to therapies. Correlative studies may be associated with a past, ongoing, or future clinical trial in order to associate various factors (genetic, DOD FY24 Ovarian Cancer Clinical Trial Translational Endpoints Research Award 4

biochemical, environmental and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. The proposed research may be hypothesis testing or may be designed to generate new hypotheses to be tested in follow-up clinical research. The award may not be used to directly support a clinical trial.

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

DISPLAYING: Synopsis 1

General Information

Document Type: Grants Notice
Funding Opportunity Number: HT942524OCRPCTTERA
Funding Opportunity Title: DoD Ovarian Cancer Clinical Trial Translational Endpoints Research Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 1
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Mar 26, 2024
Last Updated Date: Mar 26, 2024
Original Closing Date for Applications:
Current Closing Date for Applications: Aug 06, 2024
Archive Date: Sep 05, 2024
Estimated Total Program Funding: $1,600,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description:

The FY24 OCRP Clinical Trial Translational Endpoints Research Award intends to support correlation of clinical trial-related data (e.g., biosample analysis, imaging, or epidemiological data) with clinical outcomes or responses to therapies. Correlative studies may be associated with a past, ongoing, or future clinical trial in order to associate various factors (genetic, DOD FY24 Ovarian Cancer Clinical Trial Translational Endpoints Research Award 4

biochemical, environmental and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. The proposed research may be hypothesis testing or may be designed to generate new hypotheses to be tested in follow-up clinical research. The award may not be used to directly support a clinical trial.

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

Folder 353198 Full Announcement-FY24 OCRP CTTERA -> HT9425-24-OCRP-CTTERA_GG.pdf

Packages

Agency Contact Information: CDMRP Help Desk
Phone: 301-682-5507
Email: help@eBRAP.org
Email: help@eBRAP.org
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00285576 Mar 26, 2024 Aug 06, 2024 View

Package 1

Mandatory forms

353198 RR_SF424_5_0-5.0.pdf

353198 AttachmentForm_1_2-1.2.pdf

353198 RR_PersonalData_1_2-1.2.pdf

353198 RR_KeyPersonExpanded_4_0-4.0.pdf

353198 RR_Budget_3_0-3.0.pdf

353198 PerformanceSite_4_0-4.0.pdf

Optional forms

353198 RR_SubawardBudget30_3_0-3.0.pdf

2025-07-12T09:54:38-05:00

Share This Post, Choose Your Platform!

About the Author: